These results provide an answer to the clinical question “Is it effective to continue anti-HER2 therapy on disease progression in patients with metastasis or recurrence of HER2-positive breast cancer while undergoing trastuzumab therapy or after completing the therapy?” posed by the Japanese Breast Cancer Society [57]. The gene discussed is ERBB2; the disease is breast carcinoma.